Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

DOH, NTF to finalize vaccine priority criteria

Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

The Department of Health yesterday affirmed the national government’s commitment to provide all Filipinos equitable access to Covid-19 vaccines following the prioritization criteria and list approved by the Inter-Agency Task Force for the Management of Emerging Infectious Diseases.

The agency issued a statement in response to an unofficial draft of a DOH Administrative Order that have circulated online, outlining select sections of the Implementing Rules and Regulation (IRR) of Republic Act 11525, or the Covid-19 Vaccination Law, being prepared.

“The development of the IRR is guided by the principles of equal respect, national equity and legitimacy, found in the WHO SAGE (World Health Organization Strategic Advisory Group of Experts) Values Framework,” the DOH stated.

“Any provisions that may be perceived to discriminate against any sector of the population from accessing Covid-19 vaccines is not considered in any policy, guideline, protocol that shall be issued by this government,” it added.

To date, the DOH and other government agencies comprising the vaccine cluster of the National Task Force Against Covid-19 are still in the process of reconciling the proposed provisions with other existing laws and guidelines.

Stressing that the contents of the draft IRR were based on recommendations of different stakeholders, the DOH said the national government commits to honor the multiparty agreement among the DOH, NTF, vaccine manufacturers, and other procuring entities like private companies and local government units.

“All comments and recommendations from different stakeholders are still welcome until the finalization and approval of the IRR,” it added.*PNA

ARCHIVES

Read Article by date

April 2024
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 

Get your copy of the Visayan Daily Star everyday!

Avail of the FREE 30-day trial.